Man sucked into MRI machine dies from injuries, Long Island police say
Nassau County police said the man, 61, was wearing a large metallic chain and entered an MRI room while a scan was in progress Wednesday at Nassau Open MRI in Westbury.
The magnetic machine pulled the chain around his neck, causing him to be drawn in as well.
Police said a witness told them he defied orders to stay out of the room after he heard a patient, his relative, screaming during the scan.
The man died from his injuries the day after the incident, police said.
MRI machines can be especially dangerous around people with oxygen tanks, in wheelchairs or wearing magnetic jewelry. That's why patients are told to remove all metal and electrical objects before getting scanned, doctors and staff at North Shore University Hospital told CBS News New York.
"It would act like a torpedo trying to get into the middle of the center of the magnet," Charles Winterfeldt, the hospital's director of imaging services, said.
"The dangers could be catastrophic and it underscores why we have all the safety precautions in place," Dr. Payal Sud said.
Still, experts say injuries and deaths tied to MRI machines are rare when magnets pull an object from inside a room.
Nassau Open MRI, which has multiple locations in the New York area, declined CBS News New York's initial request for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
9 hours ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille
Yahoo
15 hours ago
- Yahoo
Cannibal robot? Scientists develop a robot that can grow and heal by eating others
This robot is not the first transformer mechanism revealed to the public, but the way it transforms is certainly novel – it grows and heals by consuming other robots. Researchers from Columbia University in the United States have developed a robot, called the Truss Link, that can detect and merge with pieces of robots nearby to fill in missing parts. "True autonomy means robots must not only think for themselves but also physically sustain themselves," Philippe Martin Wyder, lead author and researcher at Columbia Engineering and the University of Washington, wrote in a statement. Related China unveils tiny spy drone that looks like a mosquito. What other small spy drones exist? Made with magnetic sticks, the Truss Link can expand or transform from a flat shape to a 3D structure to adapt to the environment. It can also add new bits from other robots or discard old parts that are not functional anymore to increase its performance. In a video posted by the team, the robot merges with a piece nearby and uses it as a walking stick to increase its speed by more than 50 per cent. Related This new artificial muscle can move just like human muscles but it's 17 times stronger 'Gives legs to AI' Researchers named the process in which the robot self-assembles bits of other robots 'robot metabolism'. It is described as a natural biological organism that can often absorb and integrate resources. Robots like the Truss Link can 'provide a digital interface to the physical world, and give legs to AI,' according to a video produced by Columbia Engineering School. Integrated with AI, they possess great potential, experts believe. "Robot metabolism provides a digital interface to the physical world and allows AI to not only advance cognitively, but physically – creating an entirely new dimension of autonomy," said Wyder. The Truss Link could, in future, be used to help develop groundbreaking technologies spanning from marine research to rescue services to extraterrestrial life. Related Stanford engineers have taken a leaf out of nature's book to build this bird robot "Ultimately, it opens up the potential for a world where AI can build physical structures or robots just as it, today, writes or rearranges the words in your email," Wyder said. Programming robots has been a challenge for engineers; however, artificial intelligence is advancing developments in robotics. 'We now have the technology [AI] to make robots really programmable in a general-purpose way and make it so that normal people can programme them, not just specific robot programming engineers," Rev Lebaredian, vice president of Omniverse and simulation technology at Nvidia, told Euronews Next in May.
